Study detail
RecruitingPhase 1
A Phase 1, Randomized, Double-blind, Positive-controlled, Placebo-controlled, 4-Period Crossover, Thorough QT/QTc Study to Evaluate the Effect of Multiple Doses of BMS-986278 on Cardiac Repolarization in Healthy Participants
Bristol-Myers Squibb
Summary
The purpose of this study is to evaluate the effect of BMS-986278 on the cardiac repolarization in healthy participants.
Eligibility
- Age range
- 18–55 years
- Sex
- All
- Healthy volunteers
- Yes
Detailed criteria
Inclusion Criteria * Female individuals not of childbearing potential and males. * Healthy as determined by medical history, physical examination, vital signs, 12-lead ECG, and clinical laboratory assessments. * 18 to 55 years of age, inclusive, at the time of signing the informed consent with a BMI 18.0 to 32.0 kg/m2, inclusive. * Other protocol-defined Inclusion/Exclusion criteria apply.
Interventions
- DrugBMS-986278
Specified dose on specified days
- DrugPlacebo
Specified dose on specified days
- DrugMoxifloxacin
Specified dose on specified days
Location
- Worldwide Clinical TrialsSan Antonio, Texas